FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Biologics

Marks Wants Project Orbis for Cell/Gene Therapies

CBER director Peter Marks tells a conference he would like to see a Project Orbis-style multi-national effort to spur the development of cell and gene...

latest-news-card-1

FDA Learning to Combat Social Media Disinformation

The Los Angeles Times says FDA is learning how to use social media to combat those promoting disinformation and denying science.

latest-news-card-1
FDA General

DoJ Collects $2.2 Billion in 2022 False Claims Actions

The U.S. Department of Justice says over $2.2 billion was collected in settlements and judgments under the False Claims Act during fiscal year 2022.

latest-news-card-1
Biologics

Benefit-Risk is Top CBER Panel Issue: FDA

A new journal article by CBER reviewers finds uncertainty about assessment of the safety profile as a top discussion item at 24 advisory committee mee...

latest-news-card-1
Medical Devices

Hyperfine AI-Powered Software for MRI Cleared

FDA clears a Hyperfine 510(k) for its upgraded Swoop AI-powered software for use with the Swoop Portable MR Imaging System.

latest-news-card-1
Human Drugs

Ocuphire Pharma NDA for Eye Dilation Reversal

FDA accepts for review an Ocuphire Pharma NDA for Nyxol (phentolamine ophthalmic solution 0.75%) for treating pharmacologically-induced mydriasis.

latest-news-card-1
Federal Register

Info Collection Revision on Advisory Committees

Federal Register notice: FDA seeks comments on an information collection revision entitled FDA Advisory Committees; Information Collection Activities....

latest-news-card-1
Federal Register

Repackaging Propofol During Covid Guide Withdrawn

Federal Register notice: FDA announces the withdrawal of a guidance entitled Temporary Policy on Repackaging or Combining Propofol Drug Products Durin...

latest-news-card-1
Human Drugs

10% of FDA-approved Drugs Had Null Findings: JAMA

A new JAMA research article finds that between 2018 and 2021, FDA approved 210 new drugs and 21 (10.0%) were approved based on pivotal studies with nu...

latest-news-card-1
Human Drugs

Inspection Troubles Hit Biocons Avastin Biosimilar

FDA Inspection findings at Indias Biocon Biologics lead to a complete response letter on its BLA for a biosimilar version of bevacizumab (Genentechs A...